Unveiling the Future of Cancer Treatment: Kura Oncology’s Groundbreaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 EHA Congress
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress Introduction During the 2023 European Hematology Association (EHA) Congress, Kura Oncology presented late-breaking clinical data for their menin inhibitor, Ziftomenib. The data revealed promising results for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML) treated at the recommended…